Friday, January 30, 2026

APEC Guest List: Trump a “Maybe,” Kim Jong Un a “No Show”

South Korea's National Security Advisor discusses APEC summit attendance and North Korea's reluctance for dialogue while highlighting U.S.-Korea cooperation.

Trump Takes Center Stage at UN: Will His Vision Reshape Global Politics?

President Trump will address the UN, meet global leaders, and discuss key issues like Ukraine, Argentina's economy, and Middle East stability.

Democrats Under Fire: What’s Their Stance on North Korea’s Russia Deployment?

The People Power Party urged the Democratic Party to clarify its stance on North Korea's troop dispatch amid rising tensions.

Tag: pharmaceutical

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

Eli Lilly vs. Novo Nordisk: A $1.2 Billion Bet Reveals Two Very Different Futures for Obesity Drugs

Eli Lilly and Novo Nordisk are pursuing different strategies in the obesity treatment market, focusing on expansion versus core strengths.

2025’s Drug Price Revolution: What Asian Pharma Firms Need to Know About MFN Policies

Trump's second term sees U.S. drug pricing reforms and supply chain shifts, prompting South Korean firms to seize new opportunities.

JW Pharmaceutical Secures U.S. Patent for Hair Loss Drug Candidate JW0061

JW Pharmaceutical secures a U.S. patent for hair loss treatment JW0061, targeting GFRA1 receptor, ensuring market exclusivity until 2039.

Unlocking Convenience: Rolvedon’s Same-Day Chemotherapy Solution for Neutropenia Revealed

Hanmi Pharmaceutical's Rolvedon shows potential for same-day chemotherapy administration, improving patient convenience and market competitiveness.

Chinese & Indian Medical Invasion: Pharmaceutic Dependency on Risk of Essential Medicine Supply

Concerns rise over South Korea's API industry reliance on China and India, with self-sufficiency at a record low of 25.6% in 2023.

From R&D to Global Blockbuster: Fexuclue Sparks a New Vision for Daewoong

Daewoong Pharmaceutical's Fexuclue achieves rapid success with innovative marketing and aims for significant growth in treating GERD.

New Obesity Pill Could End Wegovy’s Reign, Offering Faster and Safer Results

Ildong's ID110521156 shows promise as an affordable GLP-1 obesity drug with fewer side effects, aiming to transform the treatment landscape.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.